HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent...
Pharmaceutical
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest GroupLOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We”...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas Blue Water Biotech Expands Commercial...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024ENCINITAS, Calif., June 14, 2023 (GLOBE...
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a...
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a...
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and...
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at...
SmithRx will be First PBM to Offer YUSIMRY, a Humira Biosimilar, for One-Tenth the List Price of Humira
Teaming up with Mark Cuban Cost Plus Drug Company, SmithRx will start offering members access beginning in July 2023SAN FRANCISCO,...
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023...
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Longeveron Welcomes Three New Prominent Board Members
Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of...
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich,...